dr. weber on the toxicity profile of nivolumab versus ipilimumab for melanoma
Published 6 years ago • 816 plays • Length 2:10Download video MP4
Download video MP3
Similar videos
-
1:22
dr. weber on nivolumab versus chemotherapy in advanced melanoma
-
1:28
dr. jeffery s. weber on sequencing of nivolumab, ipilimumab in metastatic melanoma
-
1:55
dr. jeffrey weber on ipilimumab for melanoma
-
1:15
dr. weber on nivolumab in the adjuvant setting for melanoma
-
1:08
dr. weber discusses toxicity of immunotherapies in melanoma
-
1:45
dr. kluger on the toxicity profile of concurrent nivolumab and ipilimumab
-
0:59
dr. weber on the fda approval for fixed-dose of nivolumab
-
1:03
dr. weber on risk and benefits with immunotherapy combos in melanoma
-
1:30
dr. kluger on toxicity of nivolumab/ ipilimumab for advanced melanoma
-
0:49
dr. weber on emerging therapies in melanoma
-
2:05
dr. jeffrey weber explores nivolumab in advanced melanoma
-
1:34
dr. sharpless on managing toxicities with nivolumab/ipilimumab in melanoma
-
1:05
dr. weber on the future of checkpoint inhibitors in melanoma
-
2:25
dr. weber on discontinuing immunotherapy in melanoma
-
1:22
dr. weber on adjuvant pembrolizumab in melanoma
-
3:24
ipilimumab side effect management in melanoma
-
2:18
dr. jeffrey weber on checkmate-064 trial for advanced melanoma
-
1:17
dr. weber on checkmate-238 compared to other trials in melanoma
-
1:17
dr. shoushtari on the role of nivolumab and ipilimumab in mucosal melanoma